Granules India Ipo Price

Granules india ipo price

Granules India Limited is an Indian pharmaceutical manufacturing company based in Hyderabad, India.

Granules india ipo price

Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets.[1][2]

History[edit]

Granules India was formed in 1984 as Triton Laboratories.

Triton produced Paracetamol API at its Bonthapally factory on the outskirts of Hyderabad.[3] Triton scientists found a more efficient way to produce the Paracetamol API, which led to lower capital and raw material requirements.[citation needed] In 1987, Triton became the only Indian company aside from Dr. Reddy’s Laboratories to export pharmaceutical products to the U.S.[citation needed]

Though Triton was growing as an API manufacturer, management decided it could create a value added version of its product.[citation needed] In order to distinguish itself from competitors, Triton management pioneered the concept of manufacturing and selling in bulk granulated Paracetamol, also known as direct compressible grade material (DC), or "PFI".[citation needed] In 1990, it opened its second manufacturing facility at Jeedimetla to produce multiple APIs.

Share View – Granules India Limited 22 November 2019

In 1991,[4] management set up a new entity, which was incorporated as Granules India Limited. Soon after Granules applied the PFI concept to other APIs, set up a PFI facility at Jeedimetla and began exporting the material to various markets including the U.S., Germany and Australia.[5]

In 1995,[4] Granules became a public company, after having initial public offerings on the Bombay and Hyderabad Stock Exchanges.[6]

In order to secure API for its Ibuprofen PFI, Granules formed a joint-venture with Hubei Biocause Heilen Pharmaceutical to create Granules Biocause in Wuhan, China.[7]

Infrastructure[edit]

Granules has seven manufacturing facilities; six are in India while the seventh is through a joint-venture with Hubei Biocase in Wuhan, China.

The company also has two research centres, at Hyderabad and Pune.

Granules india ipo price

The Gagillapur facility is located near Hyderabad and has a Finished Dosage block, a PFI block and a research & development facility.[citation needed]

Granules commissioned the world’s single largest PFI plant in Gagillapur in August 2003 with a batch size of 6 MT and an annual capacity of 7,200 MT per annum.

The plant received its US FDA approval within six months of commissioning.[citation needed]

See also[edit]

References[edit]

Granules india ipo price